News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
American Century Investment Management, Inc., along with American Century Companies, Inc. and the Stowers Institute for Medical Research, has reported a 5.1% beneficial ownership stake in AdvanSix Inc. (ASIX) common stock. This Schedule 13G filing indicates that the group collectively holds 1,363,346 shares with …
The State Teachers Retirement System of Ohio (STRS Ohio) has reported a 6.3% beneficial ownership stake in Sixth Street Specialty Lending, Inc. (TSLX) common stock. As of June 30, 2026, STRS Ohio beneficially owned over 6 million shares, holding sole voting and dispositive power …
This article provides a technical analysis of Sixth Street Specialty Lending Inc (TSLX), detailing its current price momentum score, support and resistance levels, and an overview of various technical indicators and moving averages. The analysis suggests the stock is currently suitable for range-bound swing …
Biodesix director Jack W. Schuler recently purchased 15,000 shares of the company's stock for $366,991, with the stock trading near its 52-week high after a significant 200% gain. While InvestingPro suggests the stock is overvalued, analysts maintain higher price targets. This follows Biodesix's strong …
Biodesix Director Jack Schuler recently purchased 15,000 shares of BDSX stock for $367,050, increasing his direct ownership to 555,810 shares. This transaction occurred as Biodesix shares traded down 1.8% to $23.79, despite the company surpassing quarterly earnings and revenue expectations. Analysts generally have a …
Jack W. Schuler, a major holder and emeritus director of Biodesix Inc. (BDSX), indirectly purchased 15,000 shares of common stock on August 12, 2026. The shares were bought at a weighted average price of $24.4661 per share through the Jack W. Schuler Living Trust, …
An insider at Biodesix (BDSX) recently purchased shares valued at $366,992, as disclosed in a recent SEC filing. This transaction was published on August 13, 2026, at 05:40 pm EDT, according to MT Newswires. Biodesix specializes in diagnostic solutions, particularly for lung cancer testing …
This article analyzes Sixth Street Specialty Lending Inc. (TSLX) using AI models to provide trading strategies and multi-timeframe signal analysis. Key findings indicate strong near and mid-term sentiment but a weak long-term outlook, with no resistance levels above the current price suggesting upside potential. …
Zacks Research downgraded Six Flags Entertainment (NYSE:FUN) from a "strong-buy" to a "strong sell" rating. This downgrade follows similar actions from other analysts who have reduced price targets for the company. Despite these downgrades, the overall consensus rating for Six Flags Entertainment remains "Hold," …
Biodesix, Inc. (NASDAQ:BDSX) has received a "Moderate Buy" consensus rating from five brokerages, with an average 12-month price target of $31.33. This comes as the company exceeded quarterly expectations, reporting revenues of $26.86 million and a lower-than-expected adjusted loss per share. Insider activity also …
Biodesix reaffirmed its full-year revenue guidance of $108 million to $114 million, representing approximately 25% year-over-year growth at the midpoint, and expects to achieve positive adjusted EBITDA on a run-rate basis soon. The company highlighted growth in its Nodify CDT test, driven by commercial …
Key Points CEO John Reilly acquired 15,713 shares on August 12, 2026, for a total consideration of ~$248,000. The acquisition represents a 6% increase in the executive's total equity holdings. The transaction was executed directly, bringing the reporting owner's direct position to ~298,000 shares.10 …
Biodesix (NASDAQ:BDSX) Director Jack Schuler recently purchased 13,900 shares of the company's stock for over $337,000, increasing his direct stake by 2.71%. The company reported better-than-expected quarterly revenue and EPS, although it remains unprofitable. Analysts maintain a "Moderate Buy" rating for Biodesix with an …
Biodesix Inc. (NASDAQ:BDSX) Director Jack W. Schuler recently acquired 27,600 shares of company stock for approximately $665,940 through two transactions on August 10 and 11, 2026. These purchases occurred as the stock trades near its 52-week high after a 257% year-to-date surge, despite InvestingPro …
Jack W. Schuler, a major shareholder and emeritus director of Biodesix Inc. (BDSX), has increased his holdings through open-market purchases made via the Jack W. Schuler Living Trust. Over two days, August 10 and August 11, 2026, Schuler acquired a total of 27,600 shares …
Truist Financial has reiterated its Hold rating for AdvanSix (ASIX.US) and set a target price of $18. This indicates their neutral outlook on the company's stock performance.
B. Riley has adjusted its price target for Sixth Street Specialty Lending (TSLX) to $20, down from $21, while reiterating a Buy rating on the stock. This revision suggests a slight change in the firm's valuation perspective for the company. Despite the lower price …
JPMorgan Chase & Co. has reduced its price target for Six Flags Entertainment (NYSE:FUN) from $26.00 to $22.00, while maintaining a "neutral" rating, suggesting a potential upside of approximately 36% from its current share price of $16.16. Despite this, analyst views are mixed, with …
Sixth Street Specialty Lending released an investor presentation detailing its debt financing and leverage metrics. The company reported $1.53 billion in commitments under its revolving credit facility and $1.55 billion in unsecured notes. Debt-to-equity increased to 1.27x as of June 30, 2026, with total …
Sixth Street Specialty Lending (TSLX) reported Q2 results with a revenue decline but beat analyst expectations. Management highlighted increased repayment activity and stable credit quality. Key analyst questions focused on portfolio turnover, the Structured Credit Partners JV's ramp and yield, pipeline activity translating to …
HC Wainwright has updated its Q3 2026 EPS estimates for Biodesix (NASDAQ:BDSX), lowering it to a loss of $0.75 per share, while maintaining a "Buy" rating and a $27 price target. This follows Biodesix's recent Q2 earnings report where the company surpassed analyst expectations, …
AdvanSix reported a 26% surge in nylon sales and an 18% increase in chemical intermediates sales in Q2 2026, despite a subdued industrial demand environment. Total company sales rose 3% year-over-year, driven by favorable pricing, though net income and EPS significantly declined. The company …
Truist Financial has lowered its price target for AdvanSix (NYSE:ASIX) to $18.00 from $20.00, while maintaining a "hold" rating, suggesting a potential upside of 10.4% from the previous close. This adjustment comes after AdvanSix missed its quarterly earnings and revenue expectations. The consensus among …
Six Flags Entertainment reported past second-quarter 2026 results showing sales of US$120.47 million and revenue of US$864.92 million, with net loss widening to US$202.62 million and loss per share of US$1.99 from continuing operations. Despite these larger losses, management highlighted higher same-park attendance, improved …
Keefe, Bruyette & Woods has increased its price target for Sixth Street Specialty Lending (NYSE:TSLX) to $19.50 from $18.50, maintaining an "outperform" rating. This implies a potential upside of 4.05% from the current stock price. The company recently surpassed quarterly earnings and revenue expectations, …
Canaccord Genuity has maintained a 'Buy' rating for Biodesix (BDSX) and increased its price target from $27.00 to $35.00, indicating strong confidence in the company's future. While analysts are optimistic about Biodesix's growth, particularly in medical diagnostics, the stock is considered modestly overvalued according …
Canaccord Genuity Group has increased its price target for Biodesix (NASDAQ:BDSX) to $35 from $27, maintaining a "buy" rating and implying a significant upside of 48.94%. This positive forecast aligns with a "Moderate Buy" consensus rating from other analysts, supported by the company's recent …
Canaccord has increased its price target for Biodesix Inc. (NASDAQ:BDSX) to $35 from $27, maintaining a Buy rating, due to higher revenue projections for 2026 and beyond. This adjustment follows Biodesix's strong second-quarter 2026 results, which surpassed estimates, driven by increased Nodify test volume …
Search by ticker symbol or company name and select a result to open its chart.